4‐(Di‐/Trifluoromethyl)‐2‐heterabicyclo[2.1.1]hexanes: Advanced Fluorinated Phenyl Isosteres and Proline analogues
作者:Anton A. Homon、Oleksandr V. Hryshchuk、Olha V. Mykhailenko、Bohdan V. Vashchenko、Kostiantyn P. Melnykov、Oleg M. Michurin、Constantin G. Daniliuc、Igor I. Gerus、Volodymyr O. Kovtunenko、Ivan S. Kondratov、Oleksandr O. Grygorenko
DOI:10.1002/ejoc.202100414
日期:2021.12.21
A robust gram-scale synthesis, physico-chemical characterization, and lead-likeness assessment of novel 4-di/trifluoromethyl-2-heterabicyclo[2.1.1]hexane building blocks as fluorinated 2,4-methanoproline analogues and phenyl isosteres are disclosed.
Compounds of formula (I)
are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
Synthesis of 1,3-bifunctional cyclobutane derivatives with α-CHF2/CF3 group – advanced building blocks for medicinal chemistry
作者:Anton A. Homon、Lada V. Shynder、Oleksandr P. Demchuk、Oleksandr V. Hryshchuk、Ivan S. Kondratov、Igor I. Gerus、Oleksandr O. Grygorenko
DOI:10.1016/j.jfluchem.2022.110041
日期:2022.11
Efficientsynthesis of novel α-CF3/CHF2-substituted 1,3-bifunctional cyclobutane building blocks – conformationallyrestricted analogs of γ-amino- and γ-hydroxybutyric acids – important neurotransmitters, as well as fluorinated derivatives of 3-oxocyclobutanecarboxylic acid – a bulk reactant widely used in synthetic and medicinal chemistry, is described. The target products were obtained on a gram
高效合成新型 α-CF 3 /CHF 2 -取代的 1,3-双功能环丁烷结构单元- γ-氨基和 γ-羟基丁酸的构象受限类似物 - 重要的神经递质,以及 3-氧代环丁烷羧酸的氟化衍生物 -描述了一种广泛用于合成和药物化学的本体反应物。目标产物以克级的形式作为单一 (1 s n ,3 s n ) 非对映异构体获得,这得益于该工艺对 CF 3取代衍生物的良好非对映选择性以及对两个系列的非对映异构体分离。
Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
申请人:Abbott Laboratories
公开号:EP2386556A1
公开(公告)日:2011-11-16
Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).